O-linked β-N-acetylglucosaminidase inhibitor attenuates β-amyloid plaque and rescues memory impairment

Neurobiology of Aging

Volumn 34, Issue 1, 2013, Pages 275-285

  Kim, Chaeyoung ^a   Nam, Dong Woo ^a   Park, Sang Yoon ^b   Song, Hyundong ^a   Hong, Hyun Seok ^a,c   Boo, Jung Hyun ^a   Jung, Eun Sun ^a   Kim, Yoonhee ^a   Baek, Ju Yuel ^b   Kim, Kwan Soo ^b   Cho, Jin Won ^b   Mook Jung, Inhee ^a  

^a Seoul National University   (South Korea)

^b Yonsei University   (South Korea)

^c Medifron DBT   (South Korea)

Author keywords

Amyloid (A ); 5XFAD transgenic mouse; Alzheimer's disease (AD); NButGT; Nicastrin; O GlcNAcylation

Indexed keywords

1,2 DIDEOXY 2' PROPYL ALPHA DEXTRO GLUCOPYRANOSO [2,1 D] DELTA2' THIAZOLINE; AMYLOID BETA PROTEIN; ENZYME INHIBITOR; GAMMA SECRETASE; N ACETYL BETA GLUCOSAMINIDASE; NICASTRIN; UNCLASSIFIED DRUG;

ACYLATION; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS INHIBITION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANALYSIS OF VARIANCE; ANIMALS; BETA-N-ACETYLHEXOSAMINIDASES; BICYCLO COMPOUNDS, HETEROCYCLIC; CONDITIONING (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEAR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEK293 CELLS; HUMANS; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; MUTATION; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; PRESENILIN-1; PRESENILIN-2; TRANSFECTION;

EID: 84868101106     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.03.001     Document Type: Article

References (34)

1. Butkinaree C., Park K., Hart G.W. O-linked beta-N-acetylglucosamine (O-GlcNAc): extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim. Biophys. Acta 2010, 1800:96-106.
2. Chalkley R.J., Burlingame A.L. Identification of novel sites of O-N-acetylglucosamine modification of serum response factor using quadrupole time-of-flight mass spectrometry. Mol. Cell. Proteomics 2003, 2:182-190.
3. De Strooper B. Nicastrin: gatekeeper of the gamma-secretase complex. Cell 2005, 122:318-320.
4. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998, 391:387-390.
5. Farmery M.R., Tjernberg L.O., Pursglove S.E., Bergman A., Winblad B., Näslund J. Partial purification and characterization of gamma-secretase from post-mortem human brain. J. Biol. Chem 2003, 278:24277-24284.
6. Griffith L.S., Mathes M., Schmitz B. Beta-amyloid precursor protein is modified with O-linked N-acetylglucosamine. J. Neurosci. Res 1995, 41:270-278.
7. Hong H.S., Hwang J.Y., Son S.M., Kim Y.H., Moon M., Inhee M.J. FK506 reduces amyloid plaque burden and induces MMP-9 in AbetaPP/PS1 double transgenic mice. J. Alzheimers Dis 2010, 22:97-105.
8. Iwatsubo T. The gamma-secretase complex: machinery for intramembrane proteolysis. Curr. Opin. Neurobiol 2004, 14:379-383.
9. Jacobsen K.T., Iverfeldt K. O-GlcNAcylation increases non-amyloidogenic processing of the amyloid-beta precursor protein (APP). Biochem. Biophys. Res. Commun 2011, 404:882-886.
10. Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng 2001, 17:157-165. 10.1016/S1389-0344(01)00067-3.
11. Jin S.M., Cho H.J., Jung M.W., Mook-Jung I. DNA damage-inducing agent-elicited gamma-secretase activity is dependent on Bax/Bcl-2 pathway but not on caspase cascades. Cell Death Differ 2007, 14:189-192.
12. Karlström H., Bergman A., Lendahl U., Näslund J., Lundkvist J. A sensitive and quantitative assay for measuring cleavage of presenilin substrates. J. Biol. Chem 2002, 277:6763-6766.
13. Kim S.H., Ikeuchi T., Yu C., Sisodia S.S. Regulated hyperaccumulation of presenilin-1 and the "gamma-secretase" complex. Evidence for differential intramembranous processing of transmembrane substrates. J. Biol. Chem 2003, 278:33992-34002.
14. Kimura R., Ohno M. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol. Dis 2009, 33:229-235.
15. Kochi S., Takanaga H., Matsuo H., Naito M., Tsuruo T., Sawada Y. Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells. Eur. J. Pharmacol 1999, 372:287-295. 10.1016/S0014-2999(99)00247-2.
16. Kreppel L.K., Blomberg M.A., Hart G.W. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J. Biol. Chem 1997, 272:9308-9315.
17. Lalonde R. The neurobiological basis of spontaneous alternation. Neurosci. Biobehav. Rev 2002, 26:91-104. 10.1016/S0149-7634(01)00041-0.
18. Lester-Coll N., Rivera E.J., Soscia S.J., Doiron K., Wands J.R., de la Monte S.M. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J. Alzheimers Dis 2006, 9:13-33.
19. Liu Y., Liu F., Iqbal K., Grundke-Iqbal I., Gong C.X. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 2008, 582:359-364.
20. Macauley M.S., He Y., Gloster T.M., Stubbs K.A., Davies G.J., Vocadlo D.J. Inhibition of O-GlcNAcase using a potent and cell-permeable inhibitor does not induce insulin resistance in 3T3-L1 adipocytes. Chem. Biol 2010, 17:937-948.
21. Macauley M.S., Shan X., Yuzwa S.A., Gloster T.M., Vocadlo D.J. Elevation of Global O-GlcNAc in rodents using a selective O-GlcNAcase inhibitor does not cause insulin resistance or perturb glucohomeostasis. Chem. Biol 2010, 17:949-958.
22. Macauley M.S., Whitworth G.E., Debowski A.W., Chin D., Vocadlo D.J. O-GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors. J. Biol. Chem 2005, 280:25313-25322.
23. McGeer E.G., McGeer P.L., Akiyama H., Harrop R. Cortical glutaminase, beta-glucuronidase and glucose utilization in Alzheimer's disease. Can. J. Neurol. Sci 1989, 16(Suppl 4):511-515.
24. Moon M., Choi J.G., Nam D.W., Hong H.S., Choi Y.J., Oh M.S., Mook-Jung I. Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-beta1-42 oligomer-injected mice. J. Alzheimers Dis 2011, 23:147-159.
25. Morais V.A., Crystal A.S., Pijak D.S., Carlin D., Costa J., Lee V.M., Doms R.W. The transmembrane domain region of nicastrin mediates direct interactions with APH-1 and the gamma-secretase complex. J. Biol. Chem 2003, 278:43284-43291.
26. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. Off. J. Soc'Y Neurosci 2006, 26:10129-10140.
27. Robertson D.M., Stephenson T., McLachlan R.I. Characterization of plasma inhibin forms in fertile and infertile men. Hum. Reprod 2003, 18:1047-1054.
28. Shah S., Lee S.F., Tabuchi K., Hao Y.H., Yu C., LaPlant Q., Ball H., Dann C.E., Südhof T., Yu G. Nicastrin functions as a gamma-secretase-substrate receptor. Cell 2005, 122:435-447.
29. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., McKay D.M., Tintner R., Frangione B., et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992, 258:126-129.
30. Tallent M.K., Varghis N., Skorobogatko Y., Hernandez-Cuebas L., Whelan K., Vocadlo D.J., Vosseller K. In vivo modulation of O-GlcNAc levels regulates hippocampal synaptic plasticity through interplay with phosphorylation. J. Biol. Chem 2009, 284:174-181.
31. Vosseller K., Wells L., Lane M.D., Hart G.W. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:5313-5318.
32. Wells L., Vosseller K., Hart G.W. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 2001, 291:2376-2378.
33. Yang Z., Herd G.A., Clarke S.M., Tajbakhsh A.R., Terentjev E.M., Huck W.T. Thermal and UV shape shifting of surface topography. J. Am. Chem. Soc 2006, 128:1074-1075.
34. Yuzwa S.A., Macauley M.S., Heinonen J.E., Shan X., Dennis R.J., He Y., Whitworth G.E., Stubbs K.A., McEachern E.J., Davies G.J., Vocadlo D.J. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat. Chem. Biol 2008, 4:483-490.